JPRN-jRCTs061210028招募中未知
nblinded, randomized, parallel-group, comparative study on preventionof oral complications by using a probiotic lozenge in chemotherapy patients with breast cancer
Kawaguchi Hiroyuki0 个研究点目标入组 60 人开始时间: 2021年8月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Age 20 years or older at the time of obtaining consent
- •2.Those who are scheduled to receive chemotherapy for breast cancer.
- •(docetaxel therapy : using docetaxel or TC therapy: using paclitaxel and carboplatin, not limited to the first treatment)
- •3.Those who have Grade 1 or less of oral mucositis due to other chemotherapeutic agents within the pre-observation period.
- •4.Those who can provide written consent for participation in this study
排除标准
- •1.Those who have taken a probiotic preparation within the last 3 months prior to the start of the study.(General lactic acid bacteria preparations such as yogurt are excluded.)
- •2.Those who have had serious side effects with probiotic pre parations in the past
- •3.Those who develop oral mucositis due to physical irritation such as dental caries, non-conforming prosthesis
- •4.Any person who, while participating in this research, participates in any other clinical research using the food or research procedures being studied
- •5.Any other person deemed inappropriate by the principal investigator or sub-investigator
研究者
相似试验
进行中（未招募）
1 期
The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patientsCD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance at least 6 monthsEUCTR2013-005506-56-HRMabion SA140
进行中（未招募）
1 期
The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patientsCD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance at least 6 monthsEUCTR2013-005506-56-PLMABION S.A.140
进行中（未招募）
不适用
Randomised, double-blind, parallel-group, comparative study of two terbinafine productsEUCTR2008-007067-16-CZJELFA SA
尚未招募
2 期
To study the safety and efficacy of Vitamin D3, Vitamin K2-7 & magnesium , in prevention of COVID 19 infection in health care professional (HCP)CTRI/2020/06/026191Suraksha Pharma Private Limited
进行中（未招募）
1 期
Bioequivalence trial of MabionCD20® (Mabion SA) compared to reference product: MabThera® (rituximab, Roche) in Patients with Rheumatoid ArthritisActive Rheumatoid ArthritisMedDRA version: 17.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-003194-25-HRMabion S.A.863